focus -WSS

focus

author：focus 2025-08-12 09:10:40 - browse：3

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： The new HIV moral panic

knowledge

focus

WSS

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

VC firm RA Capital starts a new synthetic biology incubator

As the dark side of IVF slowly comes into focus, even more transparency is needed

Europe sees delivery challenges ahead on Alzheimer's therapies

Congress: Eradicate hepatitis C and reduce the deficit

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

The high cost of giving birth even with insurance

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

The high cost of giving birth even with insurance

Blood tests recalled over risk of missed heart attack diagnosis

Activists slam private health insurers over coverage restrictions

As the dark side of IVF slowly comes into focus, even more transparency is needed

In Memoriam: Notable people who died in 2023

Involuntary treatment for addiction doesn't work

BioMarin wins approval for gene therapy to treat hemophilia A

The new HIV moral panic

Wikipedia

An outrageous hospital charge: I paid $710 for an hour of babysitting

Behind warning on Apellis’s eye drug lies a conflict of interest

Does aspartame cause cancer? What new WHO guidance says

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Ford recalls 870K F

Hospitals, health systems can help patients avoid medical debt

knowledge

knowledge

focus

hotspot